Skip to main content
OpenTrials
Completed

NCT Number: NCT02880033

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development.

The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo.

PBMC and platelets will be stored for future analyses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Amyotrophic Lateral Sclerosis Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Iron Metabolism Disorders Iron Overload Metabolic Diseases Motor Neuron Disease Movement Disorders Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Oxidative Stress Parkinson Disease Parkinsonian Disorders Proteostasis Deficiencies Spinal Cord Diseases Synucleinopathies TDP-43 Proteinopathies

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Roger Salengro, CHRU de Lille

Lille, France

About this study

The study collection of PBMC and platelets from 30 patient having Parkinson's disease 30 patients having Amyotrophic lateral sclerosis and 30 healthy controls.

The collection will be performed either by cytapheresis for half of the patient and by collecting the whole blood for the other half.

PBMC and platelets will be stored at minus 80°C. PBMC of patients and controls are exposed ex vivo to different pathological condition (mainly Hydrogen peroxide, menadione, hypoxia...) with and without deferiprone to analyse whether the level of oxidative stress (Reactive Oxygen Species and notably hydroxyl radical with hydroxypethidine probe with flow cytometry) is reduced under deferiprone (primary criterion. Secondary analyses will concern the level of iron, the energy metabolism (aerobic versus anaerobic and the level of Adenosine triphosphate production), the type of cell death (apoptosis, autophagy and new programmed cell death: Ferroptosis) and inflammation. Finally, the level of growth factors and their effectiveness will be studied from platelets.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Parkinson's disease according to Movement Disorders Society criteria
  • Amyotrophic Lateral Sclerosis according to El escorial criteria
  • Age and sex matched healthy controls

Exclusion criteria

  • Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)

Treatment and study plan

Deferiprone

Drug

to test the action of deferiprone on lymphocytes from patients and controls ex vivo

Other names: FERRIPROX

Placebo

Drug

to control the action of placebo on lymphocytes from patients and controls ex vivo

Primary outcomes

  1. hydroxyl radical measured

    Time frame: 12 months

    hydroxypethidine probe with Fluorescence-activated cell sorting

Secondary outcomes

  1. adenosine triphosphate production measured by seahorse

    Time frame: 12 months

    seahorse experimentation

  2. oxygen consumption measured by seahorse

    Time frame: 12 months

    seahorse experimentation

  3. free reactive iron (ferrous iron)

    Time frame: 12 months

    calceine assay

  4. lipid peroxidation measured by Fluorescence-activated cell sorting

    Time frame: 12 months

    flow cytometry with bodipy probe

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Official study title

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Acronym: LymphoEnergy

Important dates

Study start
2011
Primary completion
2019
Study completion
2020
First posted
Aug 26, 2016
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.